Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 20
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, reported final results from the Phase 2, open-label ENCORE 303 trial in post-menopausal women with advanced, estrogen receptor positive breast cancer who were progressing on aromatase inhibitor therapy.
Linear Mode
